Dynamic Expansion Culture for Mesenchymal Stem Cells
To be applied in sufficient numbers for regenerative medicine, primary mesenchymal stem cells (MSCs) need to be amplified in culture. Standard cell culture involves regular passing because MSC proliferation in size-limited culture vessels stagnates due to contact inhibition of growth. The use of harmful enzymes for passaging and the mechanical properties of standard culture vessels change the MSC phenotype. Initially, fast growing multipotent and regenerative MSCs will turn into slowly growing cells with reduced multipotency and fibrotic character. We here describe an innovative culture system that maintains overall constant cell densities which are near-optimal for proliferation, while preventing contact-inhibition of cell growth. This is achieved by dynamically enlarging a novel highly elastic culture dish using a motorized mechanical device and adapting the culture surface to the increasing cell numbers. Dynamic MSC culture expansion reduces the number of enzymatic passages by a factor of 3 and delivers higher MSC yields than conventional culture. On the expanded culture surface, MSCs maintain stem cell characteristics and high growth rates over months and are still inducible to follow different lineages thereafter.
Key wordsHighly elastic silicone rubber MSC culture Passaging Surface functionalization Fibrosis
This work was financed by the GEBERT RÜF STIFTUNG and the Collaborative Health Research Programme CIHR/NSERC (CHRP), grant #1004005 (to BH and TMQ) and the Canadian Institutes of Health Research (#488342) (to BH).
- 10.Hinz, B. (2010), The myofibroblast – friend or foe in regenerative medicine ? In Regenerative medicine and biomaterials for the repair of connective tissues, C.A.J. Ralphs, Editor. Woodhead: Cambridge.Google Scholar
- 12.Breitbach, M., Bostani, T., Roell, W., Xia, Y., Dewald, O., Nygren, J.M., Fries, J.W., Tiemann, K., Bohlen, H., Hescheler, J., Welz, A., Bloch, W., Jacobsen, S.E., and Fleischmann, B.K. (2007) Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 110, 1362–1369.PubMedCrossRefGoogle Scholar
- 15.Ninichuk, V., Gross, O., Segerer, S., Hoffmann, R., Radomska, E., Buchstaller, A., Huss, R., Akis, N., Schlondorff, D., and Anders, H.J. (2006) Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int 70, 121–129.PubMedCrossRefGoogle Scholar
- 16.di Bonzo, L.V., Ferrero, I., Cravanzola, C., Mareschi, K., Rustichell, D., Novo, E., Sanavio, F., Cannito, S., Zamara, E., Bertero, M., Davit, A., Francica, S., Novelli, F., Colombatto, S., Fagioli, F., and Parola, M. (2008) Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut 57, 223–231.PubMedCrossRefGoogle Scholar
- 23.Friedl, G., Schmidt, H., Rehak, I., Kostner, G., Schauenstein, K., and Windhager, R. (2007) Undifferentiated human mesenchymal stem cells (hMSCs) are highly sensitive to mechanical strain: transcriptionally controlled early osteo-chondrogenic response in vitro. Osteoarthritis Cartilage 15, 1293–1300.PubMedCrossRefGoogle Scholar